Research advance on difference of efficacy and prognosis of tyrosine kinase inhibitor treatment for advanced non-small cell lung cancer patients with 19del and L858R mutation
10.3760/cma.j.issn.1008-1372.2019.11.046
- VernacularTitle: 19del与L858R的晚期非小细胞肺癌TKI治疗疗效及预后差异的研究进展
- Author:
Yan LI
1
;
Xingxiang XU
2
Author Information
1. Graduate School, Dalian Medical University, Dalian 116044, China
2. Graduate School, Dalian Medical University, Dalian 116044, China; Department of Respiratory Medicine, Subei People′s Hospital of Jiangsu Province, Yangzhou 225001, China
- Publication Type:Review
- Keywords:
Carcinoma, non-small-cell lung;
Receptor, epidermal growth factor;
Protein kinase inhibitors;
Exons;
ErbB receptors;
Review
- From:
Journal of Chinese Physician
2019;21(11):1758-1760,f3
- CountryChina
- Language:Chinese
-
Abstract:
The epidermal growth factor receptor (EGFR) exon 19 deletion (19del) and the L858R point mutation of exon 21 are the most common types of EGFR mutations in non-small cell lung cancer (NSCLC). Treatment with EGFR tyrosine kinase inhibitors (TKI) can provide better survival benefit for some patients with advanced NSCLC. Clinical studies have shown that patients with these two types of mutations have different benefits in EGFR-TKI therapy. However, most patients treated with EGFR-TKI develop resistance after 12 months of treatment, the most common of which is the EGFR gene T790M mutation. In order to study the mechanism of resistance to TKI in NSCLC patients, and to develop new therapeutic methods and rational treatment strategies, further research on tumor characteristics in the whole disease progression and treatment process is indispensable. Exploring and comparing the differences between 19del and L858R and T790M in obtaining resistance to TKI is of great clinical significance.
